Companion Animal Arthritis - Global Stategic Business Report

The global market for Companion Animal Arthritis was estimated at US$3.4 Billion in 2024 and is projected to reach US$4.8 Billion by 2030, growing at a CAGR of 6.0% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Companion Animal Arthritis market.

Global Companion Animal Arthritis Market - Key Trends & Drivers Summarized

What is Driving the Rise in Companion Animal Arthritis Cases?

Arthritis in companion animals, particularly dogs and cats, has been on the rise due to several factors, including increased pet longevity, obesity prevalence, and greater awareness among pet owners. Veterinary advancements and improved diagnostic capabilities have contributed to the identification of arthritis cases that might have otherwise gone unnoticed. As more households treat pets as family members, the demand for high-quality veterinary care, including arthritis management solutions, has surged significantly. Additionally, the growing geriatric pet population has placed arthritis management at the forefront of veterinary care. Many pet owners are now proactively seeking treatments ranging from traditional pharmaceuticals to holistic therapies. The expansion of companion animal insurance coverage has also made arthritis treatments more accessible, reducing financial barriers for pet owners. This trend is fueling the market’s growth, as companies develop new and improved treatment options for managing osteoarthritis and degenerative joint diseases in pets.

How Are Innovations in Veterinary Medicine Transforming Arthritis Treatment?

Veterinary medicine has seen significant breakthroughs in arthritis treatment, with a shift toward more sophisticated, multi-modal approaches. Non-steroidal anti-inflammatory drugs (NSAIDs) remain a primary treatment option, but there is increasing interest in regenerative medicine, including stem cell therapy and platelet-rich plasma (PRP) treatments. These therapies are gaining traction due to their potential to repair damaged tissues and improve mobility without the side effects associated with long-term NSAID use. The introduction of monoclonal antibodies specifically designed to target pain receptors in arthritic animals marks another significant milestone in the market. These novel biologics offer extended pain relief with fewer adverse reactions compared to traditional pain management methods. Additionally, advancements in nutraceuticals, including omega-3 fatty acids, glucosamine, and chondroitin supplements, are driving growth in the arthritis management segment. Manufacturers are now focusing on developing palatable formulations that encourage compliance among pet owners and ensure optimal therapeutic benefits.

Why Is the Market Seeing a Surge in Non-Pharmaceutical Therapies?

As concerns grow over the long-term use of pharmaceuticals, pet owners and veterinarians alike are increasingly turning to non-pharmaceutical interventions for arthritis management. Hydrotherapy, acupuncture, and therapeutic laser treatments are gaining widespread acceptance as complementary therapies that enhance mobility and reduce discomfort. These approaches are especially popular among owners who seek drug-free alternatives or wish to combine treatments for maximum effectiveness. Furthermore, advancements in wearable technology for pets are playing a crucial role in monitoring mobility and detecting early signs of joint deterioration. Smart collars and activity monitors equipped with AI-driven analytics help veterinarians and pet owners make informed decisions about arthritis management. The availability of home-based rehabilitation programs, including guided physiotherapy sessions via mobile applications, is another emerging trend, making arthritis care more accessible and personalized.

What Are the Key Growth Drivers Fueling Market Expansion?

The growth in the Companion Animal Arthritis market is driven by several factors, including the rising number of aging pets, increased pet humanization, and expanding awareness of arthritis treatment options. The rising trend of premium pet care has led to higher spending on veterinary services, pharmaceuticals, and alternative therapies. Additionally, the growing presence of specialized veterinary clinics and rehabilitation centers is contributing to the accessibility and adoption of advanced arthritis treatments. Technological innovations, particularly in biologics and regenerative medicine, are further propelling market expansion. Companies investing in research and development to create safer and more effective treatment options are seeing strong market penetration. The increasing acceptance of pet insurance, which often covers arthritis treatment costs, is making veterinary care more affordable for pet owners, encouraging higher spending on advanced therapies. Moreover, evolving consumer behavior - marked by an increasing preference for holistic, natural, and preventative healthcare solutions - is reshaping the arthritis treatment landscape. Manufacturers are responding by introducing innovative dietary supplements, functional foods, and novel drug formulations tailored to meet these demands. As awareness continues to grow and treatment options become more sophisticated, the Companion Animal Arthritis market is poised for sustained growth in the coming years.

Report Scope

The report analyzes the Companion Animal Arthritis market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments: Animal Type (Dogs, Cats, Other Animal Types); Indication (Osteoarthritis Indication, Other Indications); Treatment Type (Medications Treatment, Supplements Treatment, Other Treatment Types); Distribution Channel (Veterinary Hospitals and Clinics Distribution Channel, Online Stores Distribution Channel, Retail Pharmacies Distribution Channel, Other Distribution Channels)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Dogs segment, which is expected to reach US$2.9 Billion by 2030 with a CAGR of a 6.7%. The Cats segment is also set to grow at 5.3% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $915.1 Million in 2024, and China, forecasted to grow at an impressive 9.6% CAGR to reach $979.1 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Companion Animal Arthritis Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Companion Animal Arthritis Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Companion Animal Arthritis Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as American Regent, Inc., Aratana Therapeutics (a subsidiary of Elanco), Boehringer Ingelheim, Ceva Santé Animale, Companion Animal Health (a division of Enovis™ Corporation) and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 36 Featured):

• American Regent, Inc.
• Aratana Therapeutics (a subsidiary of Elanco)
• Boehringer Ingelheim
• Ceva Santé Animale
• Companion Animal Health (a division of Enovis™ Corporation)
• Dechra Pharmaceuticals PLC
• Elanco Animal Health
• Eltech K-Laser s.r.l
• Liquid Health Inc.
• Matsun Nutrition
• NexGen Pharmaceuticals
• Norbrook Laboratories Ltd
• Nutri-Vet, LLC
• Synflex America Inc.
• Thorne Research Inc.
• Vetalogica
• Vetbiolix
• Vetoquinol
• Virbac
• Zoetis

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What’s Included in This Edition:

• Tariff-adjusted market forecasts by region and segment
• Analysis of cost and supply chain implications by sourcing and trade exposure
• Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

• Finalized tariff impacts and new trade agreement effects
• Updated projections reflecting global sourcing and cost shifts
• Expanded country-specific coverage across the industry